APRAMEYA vs RUBICON: Stock Comparison

APRAMEYA vs RUBICON RESEARCHUpdated 18 Sept 26, 4:08 PM ISTNSE & company filings

RUBICON RESEARCH is the larger company by market capitalisation. APRAMEYA shows a lower P/E and lower leverage, while RUBICON RESEARCH shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

APRAMEYA leads 3; RUBICON leads 10 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

APRAMEYARUBICON

Valuation lens

What price are you paying?

Market CapContext only
₹217 Cr
₹29,005 Cr
P/E RatioAPRAMEYA has the lower reading
60.82x
100.45x
P/B RatioAPRAMEYA has the lower reading
0x
22.46x
EPSRUBICON has the higher reading
₹2.68
₹5.13
Book ValueContext only
₹36.54
₹77.93
Dividend YieldRUBICON has the higher reading
0%
0.09%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
RUBICON is the larger company
₹29,005 Cr vs ₹217 Cr
P/E Ratio
APRAMEYA has a lower P/E
60.82x vs 100.45x
P/B Ratio
APRAMEYA has a lower P/B
0x vs 22.46x
EPS
RUBICON has higher earnings per share
₹5.13 vs ₹2.68
Dividend Yield
RUBICON has a higher dividend yield
0.09% vs 0%
Revenue Growth (TTM YoY)
RUBICON has faster revenue growth
43.5% vs 0%
EPS Growth (TTM YoY)
RUBICON has faster EPS growth
96.6% vs 0%
Qtr Sales Growth
RUBICON has stronger quarterly sales growth
24.92% vs 0.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAPRAMEYARUBICON
SectorHealthcare
IndustryPharmaceuticals

Price

MetricAPRAMEYARUBICON
Live Price₹1,751.1
Day Change-1.53%
Volume4.7 L
52-Week High₹1,899
52-Week Low₹570.75
Distance from 52W High-7.79%

Valuation

MetricAPRAMEYARUBICON
Market Cap₹217 Cr₹29,005 Cr
P/E Ratio60.82x100.45x
P/B Ratio0x22.46x
EPS₹2.68₹5.13
Book Value₹36.54₹77.93
Dividend Yield0%0.09%

Growth

MetricAPRAMEYARUBICON
Revenue Growth (TTM YoY)0%43.5%
EPS Growth (TTM YoY)0%96.6%
Qtr Sales Growth0.7%24.92%
Qtr Profit Growth1.73%2.83%

Profitability & Leverage

MetricAPRAMEYARUBICON
ROE7.37%13.9%
ROCE10.07%13.89%
Net Margin0%13.48%
Operating Margin19.83%21.72%
Debt to Equity0.1x0.19x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricAPRAMEYARUBICON
Promoter Holding74.05% 0.52 pp23.93% 0.04 pp
FII Holding0%7.52% 0.02 pp
DII Holding0.7% 0.07 pp9.43% 0.59 pp
Public Holding25.24% 0.46 pp23.3% 0.72 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and RUBICON RESEARCH.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.